(4R,5S)-4-chloro-1-<3-oxo-3-(2-oxo-4-methyl-5-phenyl-3-oxazolidinyl)propyl>benzene | 139377-25-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4R,5S)-4-chloro-1-<3-oxo-3-(2-oxo-4-methyl-5-phenyl-3-oxazolidinyl)propyl>benzene
• 英文别名: 3-[3-(4-chloro-phenyl)-propionyl]-4-R-methyl-5-S-phenyl-oxazolidin-2-one；(4R,5S)-3-[3-(4-chlorophenyl)-propionyl]-4-methyl-5-phenyl-oxazolidin-2-one；(4R,5S)-3-[3-(4-chlorophenyl)propanoyl]-4-methyl-5-phenyl-1,3-oxazolidin-2-one
• CAS: 139377-25-6
• 化学式: C₁₉H₁₈ClNO₃
• 分子量: 343.81
• InChiKey: RSKUOSIGBZZCAI-FZKQIMNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4R,5S)-4-chloro-1-<3-oxo-3-(2-oxo-4-methyl-5-phenyl-3-oxazolidinyl)propyl>benzene 在 palladium on activated charcoal lithium hydroxide 、 2,4,6-三异丙基苯磺酰叠氮化物 、 氢气 、 双氧水 、 双(三甲基硅烷基)氨基钾 作用下， 以 四氢呋喃 、 乙醚 、 水 、 乙酸乙酯 为溶剂， -78.0~25.0 ℃ 、101.33 kPa 条件下， 反应 4.53h， 生成 methyl (R)-2-[(tert-butoxycarbonyl)amino]-3-(4-chlorophenyl)propanoate
  参考文献：
  名称：

  Model studies on the synthesis of carboxylate-binding pocket analogs of vancomycin using arene-ruthenium chemistry

  摘要：

  Preparation of several protected (D)-chlorophenylalanine derivatives in high optical purity and their complex formation with the [RuCp]+ moiety are described. The complexation reaction, as well as subsequent photochemical decomplexations, proceeds with retention of optical purity. Reactions of these chloroarene complexes with 3-hydroxyphenylglycine derivatives proceed under mild conditions to give aryl ether-ruthenium complexes, which can be converted to diaryl ethers in which both aromatic rings have protected amino acid or peptide side chains. Efforts to effect cycloamidation to give vancomycin carboxylate-binding pocket analogues, using a number of known coupling reagents, were unsuccessful.

  DOI：

  10.1021/jo00032a028
• 作为产物：
  描述：

  3-(4-氯苯基)丙酸 在 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.67h， 生成 (4R,5S)-4-chloro-1-<3-oxo-3-(2-oxo-4-methyl-5-phenyl-3-oxazolidinyl)propyl>benzene
  参考文献：
  名称：

  Model studies on the synthesis of carboxylate-binding pocket analogs of vancomycin using arene-ruthenium chemistry

  摘要：

  Preparation of several protected (D)-chlorophenylalanine derivatives in high optical purity and their complex formation with the [RuCp]+ moiety are described. The complexation reaction, as well as subsequent photochemical decomplexations, proceeds with retention of optical purity. Reactions of these chloroarene complexes with 3-hydroxyphenylglycine derivatives proceed under mild conditions to give aryl ether-ruthenium complexes, which can be converted to diaryl ethers in which both aromatic rings have protected amino acid or peptide side chains. Efforts to effect cycloamidation to give vancomycin carboxylate-binding pocket analogues, using a number of known coupling reagents, were unsuccessful.

  DOI：

  10.1021/jo00032a028

文献信息

• Melanocortin receptor ligands
  申请人：The Procter & Gamble Company

  公开号：US20030236230A1

  公开（公告）日：2003-12-25

  The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: 1 wherein preferably R is substituted aryl, W is a pendant unit having the formula: -L-Q L is a linking unit, Q is preferably a cyclic hydrocarbyl unit; W 1 is preferably a carbocyclic unit and W 2 is a heteroatom comprising unit.

  本发明涉及包含一个与取代或未取代的烃基环相连的4-取代哌啶环的化合物。这些化合物，包括所有立体异构体和对映异构体形式以及其药学上可接受的盐，具有以下结构式：其中R最好是取代芳基，W是具有以下结构式的挂链单元：-L-Q，L是连接单元，Q最好是环状烃基单元；W1最好是碳环单元，W2是含氧杂原子单元。
• AKT protein kinase inhibitors
  申请人：Mitchell S. Ian

  公开号：US20050130954A1

  公开（公告）日：2005-06-16

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供化合物，包括已解决的对映体、二对映异构体、溶剂化物和药学上可接受的盐，其包括公式：A-L-CR，其中CR是一个环核心基团，L是一个连接基团，A如此处所定义。同时提供了使用本发明化合物作为AKT蛋白激酶抑制剂和用于治疗增殖性疾病如癌症的方法。
• AKT PROTEIN KINASE INHIBITORS
  申请人：Mitchell Ian S.

  公开号：US20100168123A1

  公开（公告）日：2010-07-01

  The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

  本发明提供了化合物，包括已分离的对映体、非对映异构体、溶剂化物和药学上可接受的盐，其包括式子：A-L-CR，其中CR是一个环状核心基团，L是一个连接基团，A如上所定义。本发明还提供了使用这些化合物作为AKT蛋白激酶抑制剂和治疗增殖性疾病，如癌症的方法。
• [EN] AKT PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEINE KINASE AKT
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2005051304A3

  公开（公告）日：2006-07-27
• US7026335B2
  申请人：——

  公开号：US7026335B2

  公开（公告）日：2006-04-11